share_log

Coliseum Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing August 13, 2021

Coliseum Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing August 13, 2021

Coliseum Acquisition Corp.宣佈從2021年8月13日開始單獨交易其A類普通股和認股權證
Benzinga Real-time News ·  2021/08/10 16:35

Coliseum Acquisition Corp. (NASDAQ:MITAU) (the “Company”), a special purpose acquisition company, today announced that, commencing August 13, 2021, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares and warrants included in the units. Class A ordinary shares and warrants that are separated will trade on The Nasdaq Capital Market (“Nasdaq”) under the symbols “MITA” and “MITAW,” respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Those units not separated will continue to trade on Nasdaq under the symbol “MITAU.” Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into shares of Class A ordinary shares and warrants.

特殊目的收購公司Coliseum Acquisition Corp.(納斯達克股票代碼:MITAU)(以下簡稱“本公司”)今天宣佈,自2021年8月13日起,公司首次公開募股(IPO)中出售的單位的持有者可以選擇單獨交易單位中包含的公司A類普通股和認股權證。分離的A類普通股和認股權證將分別以“MITA”和“MITAW”的代碼在納斯達克資本市場(“納斯達克”)交易。拆分單位後,不會發行零碎認股權證,只會買賣整份認股權證。這些未分離的部門將繼續在納斯達克交易,交易代碼為“MITAU”。單位持有者需要讓他們的經紀人聯繫公司的轉讓代理機構大陸股票轉讓與信託公司,以便將單位分成A類普通股和認股權證。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

本新聞稿不應構成出售或徵求購買公司證券的要約,也不應在任何州或司法管轄區出售這些證券,在這些州或司法管轄區,根據任何州或司法管轄區的證券法,在註冊或獲得資格之前,此類要約、招攬或出售將是非法的。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論